Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 13, 2013, Pages 1802-1809

  Teunissen, Charlotte ^a   Menge, Til ^b   Altintas, Ayse ^c   Álvarez Cermeño, José C ^d   Bertolotto, Antonio ^e   Berven, Frode S ^f,g   Brundin, Lou ^h   Comabella, Manuel ⁱ   Degn, Matilde ^j   Deisenhammer, Florian ^k   Fazekas, Franz ^l   Franciotta, Diego ^m   Frederiksen, Jette L ^j   Galimberti, Daniela ⁿ   Gnanapavan, Sharmilee ^o   Hegen, Harald ^k   Hemmer, Bernhard ^p   Hintzen, Rogier ^q   Hughes, Steve ^r   Iacobaeus, Ellen ^s   Kroksveen, Ann C ^f   Kuhle, Jens ^t   Richert, John ^u   Tumani, Hayrettin ^v   Villar, Luisa M ^d   Drulovic, Jelena ^w   Dujmovic, Irena ^w   Khalil, Michael ^l   Bartos, Ales ^x,y   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c ISTANBUL UNIVERSITY   (Turkey)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

^f UNIVERSITY OF BERGEN   (Norway)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^k INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^l MEDICAL UNIVERSITY OF GRAZ   (Austria)

^m C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^p Germany 3 Munich Cluster for Systems Neurology   (Germany)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r ISIS PHARMACEUTICALS   (United States)

^s KAROLINSKA INSTITUTE   (Sweden)

^t UNIVERSITY HOSPITAL BASEL   (Switzerland)

^u BIOGEN   (United States)

^v UNIVERSITY HOSPITAL ULM   (Germany)

^w UNIVERSITY OF BELGRADE   (Serbia)

^x NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^y CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

Biomarkers; cerebrospinal fluid; control groups; study design

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; GLUCOSE; NERVE CELL ADHESION MOLECULE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CEREBROSPINAL FLUID; CONSENSUS; CONTROL GROUP; DIFFERENTIAL DIAGNOSIS; GLUCOSE BLOOD LEVEL; LUMBAR PUNCTURE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NOMENCLATURE; PRACTICE GUIDELINE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CONTENT; REVIEW; SJOEGREN SYNDROME; SPINAL ANESTHESIA; VIRUS ENCEPHALITIS; VIRUS MENINGITIS;

BIOMARKERS; CEREBROSPINAL FLUID; CONTROL GROUPS; STUDY DESIGN;

BIOLOGICAL MARKERS; CONSENSUS; CONTROL GROUPS; HUMANS; MULTIPLE SCLEROSIS; PATIENT SELECTION; RESEARCH DESIGN; TERMINOLOGY AS TOPIC;

EID: 84887524454     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513488232     Document Type: Review

References (11)

1. Gnanapavan S, Grant D, Illes-Toth E, et al. Neural cell adhesion molecule - description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol. 2010 ; 225: 118-122
2. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler. 2011 ; 17: 335-343
3. Deisenhammer F, Bartos A, Egg R, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006 ; 13: 913-922
4. Brettschneider J, Hartmann N, Lehmensiek V, et al. Cerebrospinal fluid markers of idiopathic intracranial hypertension: Is the renin-angiotensinogen system involved?. Cephalalgia. 2011 ; 31: 116-121
5. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 ; 73: 1914-1922
6. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry. 1994 ; 57: 897-902
7. Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler. 2005 ; 11: 532-536
8. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003 ; 987: 25-31
9. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
10. Deisenhammer F, Egg R, Giovannoni G, et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol. 2009 ; 16: 760-770
11. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011 ; 76: 1206-1213